A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies
Dive into the research topics of 'A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies'. Together they form a unique fingerprint.
Keyphrases
Medicine and Dentistry
Pharmacology, Toxicology and Pharmaceutical Science